Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds Casesfetal-neonatal-and-perinatal

Paeds Cases · fetal-neonatal-and-perinatal

The preterm infant who stops weaning — a haemodynamically significant PDA

OSCE on a ventilated preterm infant with a haemodynamically significant patent ductus arteriosus, testing the assessment of significance, the expectant-first management ladder, the drug doses, the trial evidence, and the exclusion of a duct-dependent circulation.

osce neonatal haemodynamics scenario
On this page & tools

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics
Prompt
A 26-week, 780 g infant at day 5 of life, ventilated for respiratory distress syndrome and previously weaning, develops bounding pulses, a hyperdynamic precordium, a widened pulse pressure of 52/24, oliguria and a creeping oxygen requirement; the candidate must assess haemodynamic significance, integrate the clinical and echocardiographic findings, institute expectant management, state the indications and doses for pharmacological closure, and exclude a duct-dependent circulation before any treatment.

Candidate brief

You are the neonatal registrar. A 26-week, 780 g infant (day 5, ventilated for respiratory distress syndrome and previously weaning) has developed bounding pulses, a hyperdynamic precordium and a widened pulse pressure (52/24), with the urine output falling to 0.8 mL/kg/h and the oxygen requirement creeping from 28% to 42%. [13] You have four minutes to assess the significance of the duct, state your immediate and stepwise management, give the drug doses you would use, and explain the safety check before any closure attempt.

Clinical information for the examiner

Setting: Tertiary NICU, day 5 of life. The infant is ventilated on volume-targeted ventilation (PIP 16, PEEP 5, rate 30, FiO₂ 0.42) for respiratory distress syndrome; antenatal steroids were given and one dose of surfactant administered at birth. The creatinine has risen from 78 to 102 µmol/L. [13]

On your arrival:

  • Heart rate 158, SpO₂ 92%, blood pressure 52/24 (mean 34), widened pulse pressure 28. [13]
  • Pulses bounding at the brachial and femoral arteries; precordium hyperdynamic. [13]
  • Soft systolic murmur at the upper left sternal border. [13]
  • Urine output 0.8 mL/kg/h (was 2.5). [13]

Functional echocardiogram (provided): structurally normal heart; duct diameter 2.1 mm with left-to-right flow; left atrial-to-aortic root ratio 1.7; diastolic flow reversal in the descending aorta; increased left ventricular output. [13]

This is a haemodynamically significant PDA

The widened pulse pressure with a low diastolic, the bounding pulses and hyperdynamic precordium, the oliguria and rising creatinine, and the echo constellation (duct over 1.5 mm, LA:Ao over 1.5, aortic diastolic flow reversal) together define a haemodynamically significant PDA. [13] The candidate must integrate the clinical end-organ signs with the echo and exclude a duct-dependent circulation before any treatment.

Task 1 — Assess haemodynamic significance (3 marks)

The candidate should integrate the bedside and echocardiographic findings. [13]

  1. Bedside shunt signature: bounding pulses, hyperdynamic precordium, widened pulse pressure with a low diastolic (52/24). [13]
  2. End-organ compromise: oliguria and rising creatinine (systemic steal), escalating oxygen need (pulmonary over-circulation). [13]
  3. Echo constellation: duct 2.1 mm, LA:Ao 1.7, diastolic flow reversal in the descending aorta. [13]

Pass criterion: candidate states that significance is a constellation integrating the clinical end-organ signs with the echo, not a single threshold, and names the key markers. [13]

Task 2 — Expectant management first (3 marks)

The candidate must lead with expectant, supportive care, not the drug cupboard. [13]

  • Correct hypoxia and acidosis (both relax the ductal smooth muscle); treat anaemia to preserve oxygen delivery. [13]
  • Lung-protective ventilation with permissive hypercapnia; avoid fluid overload and modestly restrict intake. [13]
  • Support the circulation with a vasoconstrictor if hypotension persists (volume boluses rarely help the steal); reduce or pause feeds to protect the gut. [13]
  • Trend the urine output, creatinine, blood pressure and ventilator needs serially. [13]

Pass criterion: candidate frames expectant management as an evidence-based strategy, not inaction, and cites that most ducts close spontaneously. [13]

Task 3 — Pharmacological closure and doses (3 marks)

If the end-organ compromise progresses despite supportive care, pharmacological closure is indicated. [2]

  • Ibuprofen: 10 mg/kg then 5 mg/kg at 24 and 48 hours (first-line). [2]
  • Paracetamol: 15 mg/kg every six hours — preferred here given the rising creatinine, avoiding the renal vasoconstriction of the cyclo-oxygenase inhibitors. [4]
  • Indomethacin: 0.2 mg/kg every 12 to 24 hours for three doses. [2]

Pass criterion: candidate gives correct doses and chooses paracetamol with a renal-sparing rationale, citing the Mitra network meta-analysis that all three beat placebo with ibuprofen and paracetamol favoured over indomethacin for safety. [2]

Task 4 — Evidence, safety and the ligation debate (2 marks)

Safety check: before any closure, confirm a structurally normal heart and exclude a duct-dependent circulation — closing a duct-dependent lesion is catastrophic. [13]

Evidence: the BeNeDuct trial (NEJM 2023) showed early ibuprofen was no better than expectant care, and PDA-TOLERATE showed treating at one week did not reduce death or bronchopulmonary dysplasia — anchoring the treat-the-infant approach. [1] [6]

Ligation: reserved for failure or contraindication; the association with adverse outcomes is confounded by indication (causality or bias). [10]

The marking discriminator

The candidate who reaches immediately for a cyclo-oxygenase inhibitor fails the expectant-first principle. The candidate who integrates the end-organ signs with the echo, leads with supportive care, names the correct drug doses, chooses paracetamol for the renal picture, cites BeNeDuct and PDA-TOLERATE, and excludes a duct-dependent circulation before any treatment — passes with distinction. [1] [13]

References

  1. [1]Hundscheid T, Onland W, Kooi EMW, et al Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. N Engl J Med, 2023.PMID 36477458
  2. [2]Mitra S, Florez ID, Tamayo ME, et al Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA, 2018.PMID 29584842
  3. [4]Jasani B, Mitra S, Shah PS Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev, 2022.PMID 36519620
  4. [6]Clyman RI, Liebowitz M, Kaempf J, et al PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr, 2019.PMID 30340932
  5. [10]Weisz DE, McNamara PJ Patent ductus arteriosus ligation and adverse outcomes: causality or bias? J Clin Neonatol, 2014.PMID 25024972
  6. [13]Mitra S, Weisz D, Jain A, et al Management of the patent ductus arteriosus in preterm infants. Paediatr Child Health, 2022.PMID 35273674